)
CEO Jesper Helmuth Larsen leaves AJ Vaccines A/S effective 31 January 2022. He will be succeeded by Ole Vahlgren who will assume the responsibility as CEO of AJ Vaccines A/S effective today 1 February 2022.
We are pleased to welcome Ole Vahlgren as our new CEO. He holds an extensive industry insight gained through more than 25 years as executive in leading global pharmaceutical companies.
The key priority for the new CEO is to strengthen the organisation and ready the company to further explore potential growth drivers within innovative vaccines, diagnostics and therapeutic solutions.
Ole Vahlgren has a strong track record and has showcased great personal passion and ability to grow the people around him to excel. In addition, he has extensive and well documented experience with developing pharma product portfolios as well as venture into new therapeutic areas on a global scale.
“I look forward to join AJ Vaccines. It’s a company with a strong value proposition and legacy. I see great potential for creating a sustainable growth company, and I am looking very much forward to my first day in office engaging in dialogue with the highly skilled and dedicated people”, says Ole Vahlgren.